Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives

2022/02/12 by Peter M. Irving, Krisztina B. Gecse, K Gecse · 25 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Inflammatory Bowel Disease #Pregnancy and Medication Impact #Pharmaceutical studies and practices

paper · doi:10.1053/j.gastro.2022.02.014

Abstract

Therapeutic drug monitoring (TDM) has emerged as a strategy for treatment optimization in inflammatory bowel diseases to maximize benefit and to reach more stringent, objective end points. Optimal drug concentrations in inflammatory bowel disease vary according to treatment target, disease phenotype, inflammatory burden, and timing of sampling during the treatment cycle. This review provides an update on TDM with biologic and oral small molecules, evaluates the role of reactive vs proactive TDM, and identifies the gaps in current evidence. In the future, adaptations to how we use TDM may contribute further to the goal of personalized treatment in patients with IBD.

Citations

• STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

Cited by

• Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance. [europepmc]
• 90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients. [europepmc]
• Current Role of Monoclonal Antibody Therapy in Pediatric IBD: A Special Focus on Therapeutic Drug Monitoring and Treat-to-Target Strategies. [europepmc]
• Therapeutic Drug Monitoring of Infliximab in Acute Severe Ulcerative Colitis. [europepmc]
• Exploring human biology with N-of-1 clinical trials. [europepmc]
• Revolutionizing Precision Medicine: Exploring Wearable Sensors for Therapeutic Drug Monitoring and Personalized Therapy. [europepmc]
• Therapeutic Drug Monitoring of Anti-TNFα Inhibitors: A Matter of Cut-Off Ranges. [europepmc]
• Individualized antibiotic dosage regimens for patients with augmented renal clearance. [europepmc]
• A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy. [europepmc]
• The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn's Disease with Infliximab. [europepmc]
• 3D Printing of Dietary Products for the Management of Inborn Errors of Intermediary Metabolism in Pediatric Populations. [europepmc]
• Mesenteric adipose-derived exosomal TINAGL1 enhances intestinal fibrosis in Crohn's Disease via SMAD4. [europepmc]
• Impact of antitumour necrosis factor therapy on surgery in inflammatory bowel disease: a population-based study. [europepmc]
• What are the benefits of therapeutic drug monitoring in the optimization of adalimumab therapy? a systematic review and meta-analysis up to 2022. [europepmc]
• Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations. [europepmc]
• Comparing Point-of-Care Technology to ELISA Testing for Infliximab and Adalimumab Levels in Adult Inflammatory Bowel Disease Patients: A Prospective Pilot Study. [europepmc]
• Therapeutic Drug Monitoring and Point-of-Care Technologies: Opportunities and Current Challenges. [europepmc]
• Advances in NIR-II Fluorescent Nanoprobes: Design Principles, Optical Engineering, and Emerging Translational Directions. [europepmc]
• Optimizing Drug Positioning in IBD: Clinical Predictors, Biomarkers, and Practical Approaches to Personalized Therapy. [europepmc]
• Determination of correlation of clearance with clinical outcomes for inflammatory bowel disease. [europepmc]
• Antibody-Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next-Generation Strategies Against Multidrug-Resistant Bacterial Infections. [europepmc]
• From Conventional Therapy to Precision Medicine in Inflammatory Bowel Disease: A State-of-the-Art Review. [europepmc]
• An observational cohort study evaluating adalimumab concentrations for predicting non-recapture of biochemical response after dose escalation in patients with Crohn's disease experiencing secondary loss of response. [europepmc]
• Comparison of patient-reported adverse drug reactions with pharmacovigilance records in gastrointestinal disorders. [europepmc]
• Optimizing Flumatinib Therapy in Chinese Chronic-Phase Chronic Myeloid Leukemia Based on Therapeutic Drug Monitoring. [europepmc]

Related

• Positioning and sequencing of advanced therapies in inflammatory bowel disease: A guide for clinical practice
• Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives
• On-Site Therapeutic Drug Monitoring
• In Search of Newer Targets for IBD: A Systems and a Network Medicine Approach
• Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De‐Escalation in Adults With Inflammatory Bowel Diseases